U.S. Markets open in 1 hr 27 mins

Amicus Therapeutics, Inc. (FOLD)

NASDAQ Global Market - NASDAQ Global Market Delayed Price. Currency in USD
Add to watchlist
12.41-0.10 (-0.80%)
At close: 4:00PM EDT
People also watch
ACHNTGTXHALOARRYMACK
  • W
    WILLIAM
    WILLIAM
    Someone bought around 7000 January $15.00 calls for Fold yesterday. Something up maybe?
  • M
    Matthew
    Matthew
    If the US doesn't approve galafold, it will be the ONLY major country not to do so. US approval is looking better and better every day
  • K
    Kaylee
    Kaylee
    FOLD may be a compelling opportunity. check out awesome*sto-cks, its a pretty reliable service. of course you have to do your own due diligence, but they generally point you in the right direction.
  • M
    Moe
    Moe
    Muting the homophobe billy boy blue is the best thing to do! gone!
  • P
    Pharmaherooooooo
    Pharmaherooooooo

    SLNO (MC $18 M) BLOCKBUSTER in Phase 3 /Rare Disease & Orphan Status = Undiscovered low float stock with 1000% upside Potential and more .Next FOLD in the making here .GLTA

    Soleno therapeutics (SLNO)

    Market Cap $18 Million
    Cash: $8 Million
    Price $0.37

    Shares Out: 47.6 Million ( 36 Million shares held by Insiders & Institutions)

    Initiating Coverage June 26, 2017
    http://www.lifescicapital.com/wp-content/uploads/Soleno.pdf

    •Company expects to initiate pivotal Phase III clinical trial by year-end 2017; will take approximately 9-12 months to complete

    Soleno Therapeutics, Inc. (Soleno) is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company is currently advancing its lead candidate, DCCR, a once-daily oral tablet for the treatment of PWS, into a Phase III clinical development program at the end of 2017.

    Market Opportunity for PWS is Substantial.

    While the lack of approved treatments for PWS alone make it difficult to assess the market, sales of Pfizer’s (NYSE: PFE)
    Genotrop in (somatropin) can provide some insight despite being indicate for PWS, in addition to, growth failure due to growth hormone deficiency(GHD),Turner syndrome,idiopathic short stature,and small for gestational age.This product achieved its highest revenue in 2008,with worldwide sales of approximately $900 million.While somatropin has been proven to improve growth and body composition, it does not affect the key disease component of hyperphagia and use is associated with substantial risk. Soleno is developing DCCR for the treatment of PWS,to help address the unmet need of this patient population. To assess the potential of DCCR for PWS, we performed a scenario analysis, which indicates that annual sales could be in the range of $1.1 billion given a moderate price point and 50% market penetrance.

  • B
    Bill
    Bill
    Better cover you short #$%$.
  • B
    Bill
    Bill
    Moe blows....literally and figuratively! hahahahahahaha
  • H
    Harry
    Harry
    Exciting after hours jump! Why?
  • M
    ManyLand
    ManyLand

    https://seekingalpha.com/news/3289630-amicus-galafold-okd-australia?app=1&uprof=45&dr=1#email_link

    Amicus' Galafold OK'd in Australia
    The Australian Therapeutic Goods Administration approves oral Galafold (migalastat) for the long-term treatment of patients at least 16 years old with Fabry disease who have an amenable mutation. Spon
    seekingalpha.com
  • B
    Bill
    Bill
    From now on all shorts must address ma as THE GREAT ONE!
  • B
    Bill
    Bill
    After over 2 decades of reading message boards, there is no question that HOmoe is the biggest moron to canvas there threads. He continues to get has butt kicked being short here but lacks the savvy of us good investors to admit when they are wrong. What a raging #$%$ he is! hahahahahahahahahahahahaha!!!!!!! Down over 100% is some funny stuff!
  • J
    Jennifer
    Jennifer
    FOLD, looks to be overvalued at this price Im not sure about you guys but Awe-Som.e.Sto-cks. has provided me with some pretty good trade ideas. I messed up executing some of them but thats on me.
  • m
    marc
    marc
    $500 million in cash will be enough cash until 2019, buy then revenue will be in the few hundred million range, enough to get profitable with no need for any more dilution. If your in for the long haul this will either get bought out or be a $20-30 stock. glta longs
  • B
    Bill
    Bill
    In for more at 12.74
  • B
    Bill
    Bill
    EB treatment a done deal. Homoe you are so fawked.
  • E
    Ella
    Ella
    FOLD appears to suggest upside opportunity. Ive been struggling with this stock lately. Some of my other trades have been from awe-some*sto-cks which are working out pretty well.
  • M
    Moe
    Moe

    Take a look at the order of the press release regarding their development pipeline! EB was last! Below a phase 1 molecule! Uh, why is that doc crowley?

    https://finance.yahoo.com/news/amicus-therapeutics-announces-second-quarter-110000450.html

    This is a funny quote in the press release too (stated 5 priorities but only listed 4, lol):
    "all five of our strategic priorities which include the international launch for our oral precision medicine Galafold (migalastat) for Fabry disease, the advancement of our lead clinical programs in Epidermolysis Bullosa and Pompe disease, and further strengthening of our balance sheet."

    Amicus Therapeutics Announces Second Quarter 2017 Financial Results and Corporate Updates
    179 Fabry Disease Patients on Reimbursed Galafold as of July 31– On Target to Reach 300 Patients by Year-End 2017. Migalastat NDA Submission Targeted for 4 Q17. Phase 3 EB Topline Data and Complete Phase ...
    finance.yahoo.com
  • M
    Moe
    Moe
    Incredible! only spent 5 million more in expenses this quarter to make an additional 3 million in sales! At that rate when do they need to issue more stock?
  • h
    humour412
    humour412
    Amicus Therapeutics (NASDAQ:FOLD) price target raised to $17.50 (39% upside) from $12.50 by Chardan Capital citing Galafold progress in Fabry disease and positive data on ATB200/AT2221 in Pompe disease.
  • M
    Matthew
    Matthew
    Impressed by the support at 12.50. Exited my position at 13.51 yesterday and bought back in at 12.51. Praying we don't go to war, but I don't see any other options unless Kim tucks his tail and runs. Fold is now $0.25 away from SPO of over 21 million shares. I would imagine the institutions that bought those 21 million shares don't want to lose their $$$